Cargando…

668. The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection in immunocompromised hosts, a single center study

BACKGROUND: Patients with immunocompromising conditions are at increased risk of C.difficile infection (CDI) and recurrence. Fidaxomicin reduces the risk of recurrence in immunocompetent hosts. However, there is limited data on fidaxomicin effectiveness in hosts with immunocompromising conditions. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alsoubani, Majd, Chow, Jennifer K, Rodday, Angie Mae, Kent, David, Snydman, David R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677878/ http://dx.doi.org/10.1093/ofid/ofad500.730

Ejemplares similares

669. The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection, a single center real-world experience
por: Alsoubani, Majd, et al.
Publicado: (2023)

Clostridioides difficile: A diagnostic intervention
por: Alsoubani, Majd, et al.
Publicado: (2022)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
por: Oliver, Meredith B, et al.
Publicado: (2022)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
por: Jiang, Yiling, et al.
Publicado: (2022)

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
por: Hall, Ronald G., et al.
Publicado: (2022)

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection
por: Whitney, Laura, et al.
Publicado: (2023)

Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection
por: Heleno, Caio T, et al.
Publicado: (2021)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?
por: Patel, Devangi, et al.
Publicado: (2023)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
por: Nathwani, Dilip, et al.
Publicado: (2014)

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
por: Lee, Christine, et al.
Publicado: (2016)

A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France
por: Guery, Benoit, et al.
Publicado: (2021)

692. The Role of Fidaxomicin for the Treatment of Clostridioides Difficile Infection in the Pediatric Population in the United States
por: Lee, Yuman, et al.
Publicado: (2023)

Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin
por: Sambol, Susan P., et al.
Publicado: (2023)

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
por: Figueroa, Iris, et al.
Publicado: (2012)

Whole-Genome Sequencing Demonstrates That Fidaxomicin Is Superior to Vancomycin for Preventing Reinfection and Relapse of Infection With Clostridium difficile
por: Eyre, David W., et al.
Publicado: (2014)

Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE)
por: Wolf, Joshua, et al.
Publicado: (2019)

Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
por: Crook, Derrick W., et al.
Publicado: (2012)

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses
por: Cornely, Oliver A., et al.
Publicado: (2019)

Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis
por: Brauer, Madita, et al.
Publicado: (2022)

Fidaxomicin for the Treatment of Clostridioides difficile Infection in Adult Patients: An Update on Results from Randomized Controlled Trials
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2022)

682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin
por: Thabit, Abrar K., et al.
Publicado: (2016)

Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection
por: Nerandzic, Michelle M., et al.
Publicado: (2012)

Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study
por: Wilcox, Mark H, et al.
Publicado: (2019)

797. Management of Patients with Multiple Clostridioides difficile Infection Recurrences using a Tapered-Pulsed Fidaxomicin Strategy
por: Tan, Xing, et al.
Publicado: (2020)

392. Guideline adaptation of fidaxomicin as first-line therapy for Clostridioides difficile infection in institutions across the United States
por: Basir, Angela, et al.
Publicado: (2022)

A multi-center study of fidaxomicin use for Clostridium difficile infection
por: Shah, Dhara N., et al.
Publicado: (2016)

755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults
por: Al-Bahou, Amanda, et al.
Publicado: (2021)

Fidaxomicin Inhibits Spore Production in Clostridium difficile
por: Babakhani, Farah, et al.
Publicado: (2012)

Fidaxomicin - the new drug for Clostridium difficile infection
por: Vaishnavi, Chetana
Publicado: (2015)

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI
por: Sattar, Abdul, et al.
Publicado: (2015)

397. Oral Vancomycin Versus Fidaxomicin for Clostridiodes difficile: A Comparative Retrospective Evaluation across a Large, Multi-center Healthcare System
por: Roemer, Kaleb, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q886gjmjo0j6qb7ko6h28ptjlr